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Enantiomerically Enriched α-Methyl Amino Acids. Use of an 
Acyclic, Chiral Alanine-Derived Dianion with a High 
Diastereofacial Bias.†
David B. Berkowitz and Marianne K. Smith
Department of Chemistry, University of Nebraska-Lincoln, Lincoln, NE 68588-0304
Abstract
Hindered esters derived from N-benzoylalanine and the following chiral alcohols have been 
synthesized: (1) (−)-isopinocampheol; (2) (−)-trans-2-phenylcyclohexanol and (3) (−)-8-
phenylmenthol. Sequential treatment of these esters with LDA (1.2 equiv.) and n-butyllithium (2.4 
equiv.) at −78°C in THF generates the corresponding chiral dianions. Alkylation of each of these 
with benzyl bromide reveals that only the (−)-8-phenylmenthyl auxiliary confers a high 
diastereofacial bias upon its derivative dianion. In fact, that dianion (6) consistently displays 
diastereomeric ratios in the range of 89:11 to 94:6 for alkylations with a spectrum of nine alkyl 
halides. If one recrystallization step is included, a single diastereomeric product may be obtained, 
as is demonstrated for the benzylation of 6. Of particular note, the alkylation with 3,4-bis(tert-
butyldimethylsilyloxy)benzyl bromide (18) (94:6 diast. ratio, 72% yield) constitutes a formal 
synthesis of the clinically important antihypertensive (S)-α-methyl-DOPA (Aldomet), in 
enantiomerically enriched from. In all cases studied, yields are markedly improved, yet 
diastereoselectivities unchanged, by the addition of 10% HMPA to the reaction milieu. The (−)-8-
phenylmenthol chiral auxiliary is conveniently recovered via ester cleavage with KO2/18-crown-6, 
following alkylation. Complete deprotection affords enantiomerically enriched (S)-α-methyl 
amino acids, in all cases examined, indicating that dianion 6 displays a substantial bias in favor of 
si face alkylation. This sense of diastereoselection is consistent with a chain-extended, internal 
chelate model for the reactive conformation of the dianion.
Introduction
Owing to their biological properties, both as free amino acids and as components of 
peptides, and to their conformational properties, α-methyl amino acids have assumed an 
important role in bioorganic chemistry in recent years. For example, (S)-α-methyl-DOPA 
(Aldomet), an inhibitor of DOPA decarboxylase, is an important commercial 
antihypertensive.1 Substitution of (S)-α-methyltyrosine for tyrosine-4 in angiotensin II 
results in a peptide that is resistant to chymotryptic degradation, yet retains 93% of the 
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pressor activity of the parent peptide.2 In the de novo design of peptides and proteins, several 
chiral α-methyl amino acids are useful building blocks for engineering helical secondary 
structure. For instance, (S)-isovaline (α-methylbutyrine) has been used to construct peptides 
with a 310 helical structure.3a On the other hand, (R)-α-methylaspartate is an especially 
effective building block for engineering α-helical structure.3b
For all of these applications, optically pure α-methyl amino acids are desirable. One direct 
synthetic approach to these compounds involves the α-alkylation of a chiral alanine 
equivalent. This approach has, of course, been reduced to practice with the development of 
several cyclic,4 chiral alanine-derived monoanions which display a very high diastereofacial 
bias. Perhaps, most notable among these are the bis-lactim ether of Schöllkopf,5 the 
imidazolidinones and oxazolidinones due to Seebach (self-reproduction of chirality)6 and 
the diphenyloxazinones developed by Williams.7 Ojima has also reported an acyclic4 chiral 
alanine enolate, in which chelation is elegantly used to control enolate geometry, and for 
which the chiral element resides exclusively in a β-lactam ring containing the α-amino 
group.8,9 The impressive diastereoselectivities recorded in these systems notwithstanding, a 
potential drawback to these approaches lies in the fact that, with one exception,10 the chiral 
directing element is destroyed in the process of deprotection.
We recently reported a general procedure for the synthesis of racemic, α-vinyl amino acids 
via the formal vinylation of the parent amino acids. The key step in this procedure is the 
regiospecific, α-alkylation of N-benzoyl amino ester-derived dianions11 with ethylene oxide 
as vinyl cation equivalent.12 As a first step toward developing an asymmetric version of that 
chemistry, we set out to explore the behavior of analogous chiral dianions, in which all 
stereochemical information resides in the alcoholic component of the ester functionality. In 
particular, we chose to investigate chiral alanine-derived dianions initially, as 
diastereoselective alkylation of these would provide a direct route to enantiomerically 
enriched α-methyl amino acids, with the possibility of readily recycling the chiral auxiliary.
Our strategy was based upon the following premises. It is likely that dianions derived from 
N-benzoyl-α-amino esters assume an internal chelate structure, in which the electron-rich 
amide nitrogen enters into a five-ring chelate with the lithium counterion ion of the ester, 
allowing for control of enolate geometry. It is further presumed that dianions of this type, 
bearing an auxiliary of the trans-2-alkylcyclohexyl variety, will prefer a chain-extended 
conformation over a chain-folded conformation, for steric reasons, as is illustrated in 
Scheme 1. Finally, if alkylations proceed largely through this chain-extended conformer, 
substantial diastereofacial selectivity is expected, provided that the 2-substituent is an 
effective shielding group. It is important to note that Newcomb and Bergbreiter first 
described the behavior of one such “chiral alanine dianion” a decade ago.13 In that work, the 
dianion of N-benzoylalanine (−)-menthyl ester was alkylated with three alkyl halides to 
produce protected α-methyl amino acids with modest diastereofacial selectivity 20–48% de 
[60:40 to 74:26 diast. ratios]. One is led to conclude that if the internal chelate, chain-
extended model (as illustrated in Scheme 1) correctly represents the reactive conformation 
of the dianion, then the menthyl blocking group (isopropyl) does not effectively screen the re 
face of the dianion. One could further surmise that by changing the nature of the blocking 
group one might be able to obtain high diastereofacial selectivity in the alkylation of acyclic 
Berkowitz and Smith Page 2
J Org Chem. Author manuscript; available in PMC 2018 June 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
chiral alanine dianions of this type. Following this working hypothesis, we set about to 
systematically vary the structure of the chiral auxiliary and examine its effect on 
diastereoselectivity.
We chose the inexpensive and readily available alcohol, (−)-isopinocampheol, as a baseline 
auxiliary for these studies. As illustrated in Scheme 2, one expects very limited face-
shielding with this auxiliary. On the other hand, given the impressive diastereoselectivities 
observed by Ojima and Georg14 with enolate monoanions of Whitesell [(−)-trans-2-
phenylcyclohexyl] esters in the ester enolate-imine cyclocondensation, this auxiliary 
appeared to be an obvious candidate, for which substantial diastereoface-shielding might be 
expected (Scheme 2). Finally, we chose the (−)-8-phenylmenthol (Corey) auxiliary15 to 
assess the effect of inserting a one carbon spacer between the cyclohexane ring and phenyl 
group upon diastereofacial bias of the alanine dianion.
Results and Discussion
The desired hindered esters (1–3) were obtained in nearly quantitative yield by simple fusion 
of N-benzoylalanyl chloride16 with one equivalent of isopinocampheol, trans-2-
phenylcyclohexanol, or 8-phenylmenthol, respectively, at 75°C.17 This alcohol/N-benzoyl 
amino acid chloride fusion method (98% yield, 1 h reaction time, for the phenylmenthyl 
ester of N-benzoylalanine) is clearly superior to the Harada procedure [TsOH, Dean-Stark 
trap: 58–79% yield, 30 h reaction time, for the (less hindered) menthyl ester of alanine]18 
that is typically employed to synthesize hindered esters of amino acids.13
To define the relative diastereofacial biases of dianions 4–6, each of these was subjected to 
alkylation with benzyl bromide.19–21 Not surprisingly, the isopinocampheol auxiliary 
produced little diastereoselection. On the other hand, rather unexpectedly,14 the (−)-8-
phenylmenthol-derived dianion 6 showed a much greater diastereofacial bias than the 
trans-2-phenylcyclohexanol-derived dianion 5 (Scheme 2).22 This initial screening result led 
us to pursue alkylations with dianion 6 and a considerable variety of alkyl halides.
Initially, we performed these alkylations in the absence of HMPA, and obtained the 
following yields (single runs, indexed by electrophile): benzyl bromide (32%), tert-butyl 
bromoacetate (48%), benzyloxymethyl bromide (64%), cinnamyl bromide (44%), propargyl 
bromide (33%), allyl bromide (56%), isobutyl iodide (18%). As can be seen from Table 1, in 
the presence of 10 % HMPA, yields are significantly improved for the alkylation of dianion 
6 with all alkyl halides surveyed, including the relatively hindered electrophile, isobutyl 
iodide. In all cases, the observed diastereomeric ratios were the same as those obtained in 
the absence of HMPA. This result is of practical utility and contrasts strikingly with recent 
reports of alkylations with related enolates, for which high diastereoselectivities were only 
achievable (i) by limiting the amount of additive (HMPA or TMEDA) to stoichiometric 
quantities,13b or (ii) by resorting to the use of expensive, non-lithium bases.23
Employing this procedure, one can synthesize a considerable variety of protected, α-methyl 
amino acids in diastereomeric ratios of 89:11–94:6 (78–88% de), by alkylation of dianion 6 
with the appropriate alkyl halide. Moreover, with the inclusion of a single recrystallization 
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step, one can obtain enantiomerically pure α-methyl amino acids, as has been demonstrated 
for (S)-α-methylphenylalanine.
The absolute stereochemistry of the alkylation products has been determined unambiguously 
in three cases (α-methylphenylalanine, α-methylleucine and α-methylaspartate) by 
hydrolysis (9 N HCl, reflux) of the alkylation products directly to the corresponding free, α-
methyl amino acids.24,25 Comparison of the optical rotations of these with literature values 
indicates that, at least in these cases, the absolute stereochemistry of the predominant 
enantiomer is (S), in agreement with the chain-extended, internal chelate model proposed for 
the reactive dianion conformation (Scheme 1).
While refluxing the alkylation products in aqueous HCl results in the hydrolysis of both the 
ester and amide protecting groups in a single step, it also leads to destruction of the chiral 
auxiliary. On the other hand, the (−)-8-phenylmenthol auxiliary may be conveniently 
recovered in good yield via ester cleavage with KO2/18-crown-6,26 following alkylation 
(Scheme 3). This represents an important potential practical advantage of the “chiral 
alanine” alkylation procedure described here over existing alternatives.5–9
In summary, alkylation of the acyclic, chiral alanine-derived dianion (6) with alkyl halides 
provides a convenient and direct procedure for the synthesis of enantiomerically enriched 
(78–88% ee without recrystallization, 100% ee possible with a single recrystallization) (S)-
α-methyl amino acids. The sense of diastereoselection observed is consistent with a chain-
extended, internal chelate model for the reactive conformation of the dianion. We also note 
that the enantiomeric auxiliary, (+)-8-phenylmenthol, can be readily synthesized from (−)-
citronellal,27 and so the methodology described herein could readily be applied to the 
synthesis of (R)-α-methyl amino acids,3b as well. Of particular significance, the alkylation 
with 3,4-bis(tert-butyldimethylsilyloxy)benzyl bromide (18) constitutes a formal synthesis 
of the important antihypertensive, (S)-α-methyl-DOPA (Aldomet), in enantiomerically 
enriched form. In all cases studied, yields are markedly improved, yet diastereoselectivities 
unchanged, by the addition of 10% HMPA to the reaction milieu. Furthermore, the (−)-8-
phenylmenthol auxiliary can be efficiently recycled by cleavage of the product ester with 
KO2/18-crown-6 in benzene.
Experimental Section
General
All general experimental procedures were as described previously.12 For the labeling studies,
19
 percent α-deuterium incorporation was determined by GC/MS (HP-5890 gas 
chromatograph with an HP-5972 mass spectral detector). All CI-mass spectra reported 
herein were obtained using this instrument. n-Butyllithium in hexanes (nominally 1.6 M) 
was purchased from Aldrich and titrated28 before each use.
General Procedure A
(1R,2S, 5R)-8-Phenylmenthyl N-Benzoyl-(S)-alaninate (3a)/(1R,2S, 5R)-8-
Phenylmenthyl N-Benzoyl-(R)-alaninate (3b): A mixture of (−)-8-phenylmenthol29 (3.00 
g, 12.9 mmol) and N-benzoylalanyl chloride16 (3.01 g, 14.2 mmol; freshly prepared from N-
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benzoyl-L-alanine) was heated to 78°C for 1 h. The crude product was partitioned between 
EtOAc (25 mL) and NaHCO3 (aq, 30 mL). The organic layer was dried (MgSO4), filtered, 
and evaporated. Flash chromatography (15% EtOAc/hexanes) provided 3b (1.64 g, 31%), as 
a white solid, in a first fraction, and 3a (3.52 g, 67%) also as a white solid, in a second 
fraction.
3a: mp 98–101°C; 1H NMR (500 MHz, CDCl3) δ 0.78–1.59 (m, 6 H), 0.86 (d, J = 6 Hz, 3 
H), 1.23 (s, 3 H), 1.33 (d, J = 7 Hz, 3 H), 1.33 (s, 3 H), 1.93–1.96 (m, 1 H), 2.02–2.07 (app 
dt, J = 4, 12 Hz, 1 H), 4.43 (app quintet, J = 7 Hz, 1 H), 4.92 (app dt, J = 4, 10.5 Hz, 1 H), 
6.52 (d, J = 7 Hz, 1 H), 7.09–7.11 (m, 1 H), 7.20–7.27 (m, 4 H), 7.41–7.45 (m, 2 H), 7.48–
7.51 (m, 1 H), 7.74–7.76 (m, 2 H); 13C NMR (125 MHz, CDCl3) δ 17.8, 21.6, 26.1, 27.0, 
27.5, 31.3, 34.4, 40.0, 41.6, 49.1, 50.0, 76.6, 125.4, 125.5, 127.0, 128.0, 128.5, 131.5, 134.2, 
150.7, 166.6, 172.1; MS (methane-CI) 448 (0.2, M+41), 436 (0.4, M+29), 408 [2.4, (M+H)
+], 194 (100), 176 (9.9), 105 (34). Anal. Calcd for C26H33NO3: C, 76.63; H, 8.16; N, 3.44. 
Found: C, 76.84; H, 8.41; N, 3.51.
3b: mp 98–101°C; 1H NMR (500 MHz, CDCl3) δ 0.87–1.13 (m, 3 H), 0.90 (d, J = 7 Hz, 3 
H), 1.22 (s, 3 H), 1.24 (d, J = 7 Hz, 3 H), 1.33 (s, 3 H), 1.47–1.53 (m, 1 H), 1.68–1.72 (m, 1 
H), 1.78–1.87 (m, 2 H), 2.06–2.09 (app dt, J = 4, 12 Hz, 1 H), 4.03 (app quintet, J = 7 Hz, 1 
H), 4.89 (app dt, J = 4, 10.5 Hz, 1 H), 6.42 (d, J = 7 Hz, 1 H), 7.13–7.16 (m, 1 H), 7.22–7.29 
(m, 4 H), 7.45–7.48 (m, 2 H), 7.51–7.54 (m, 1 H), 7.76–7.78 (m, 2 H); MS (methane-CI) 
448 (0.2, M+41), 436 (0.4, M+29), 408 [3, (M+H)+], 194 (100), 176 (9.2), 105 (31.7). Anal. 
Calcd for C26H33NO3: C, 76.63; H, 8.16; N, 3.44. Found: C, 76.89; H, 8.42; N, 3.53.
Determination of α-stereochemistry: From 3a (75.0 mg, 184 μmol), following General 
Procedure D, was obtained N-benzoyl-(S)-alanine (27.2 mg, 77%) as a white solid: [α]D 
+34.9° (c 1.0, CHCl3); [α]D +26.7° (c 1.0, 0.1 N NaOH) [Lit.30a [α]D = −35° (c 1.0, CHCl3) 
for the (R)-isomer; Lit.30b [α]21D = +26.7° (c 1.0, 0.1 N NaOH) for the (S)-isomer].
From 3b (75.0 mg, 184 μmol), following General Procedure D, was obtained N-benzoyl-
(R)-alanine (25.4 mg, 72%) as a white solid: [α]D −34.8° (c 1.0, CHCl3); [α]D −26.6° (c 
1.0, 0.1 N NaOH) [Lit.30a [α]D = −35° (c 1.0, CHCl3) for the (R)-isomer; Lit.30b [α]21D = 
+26.7° (c 1.0, 0.1 N NaOH) for the (S)-isomer].
(1R,2S)-2-Phenylcyclohexyl N-Benzoyl-(S)-alaninate (2a)/(1R,2S)-2-Phenylcyclohexyl 
N-Benzoyl-(R)-alaninate (2b): From (1R,2S)-2-phenylcyclohexanol31 (250 mg, 1.42 
mmol) and N-benzoylalanyl chloride16 (301 mg, 1.42 mmol), following General Procedure 
A, was obtained 2 (476 mg, 95%), as a 1.1:1 mixture of diastereomers, epimeric at the α-
carbon. Major diastereomer: 1H NMR (500 MHz, CDCl3) δ 0.86 (d, J = 7, 3 H), 1.25–1.97 
(m, 7 H), 2.13–2.15 (m, 1 H), 2.67–2.73 (m, 1 H), 4.51–4.63 (app quintet, J = 7 Hz, 1 H), 
5.04–5.09 (app dt, J = 4, 11 Hz, 1 H), 6.54 (d, J = 6 Hz, 1 H), 7.12–7.27 (m, 5 H), 7.38–7.50 
(m, 3 H), 7.69–7.71 (m, 2 H). Minor diastereomer: 1H NMR (500MHz, CDCl3) δ 1.25–1.97 
(m, 7 H), 1.28 (d, J = 7, 3 H), 2.13–2.15 (m, 1 H), 2.67–2.73 (m, 1 H), 4.45–4.53 (app 
quintet, J = 7 Hz, 1 H), 5.00–5.05 (app dt, J = 4, 11 Hz, 1 H), 6.43 (d, J = 6 Hz, 1 H), 7.12–
7.27 (m, 5 H), 7.38–7.50 (m, 3 H), 7.69–7.71 (m, 2 H). MS (2a/2b; methane-CI) 392 (1, M
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+41), 380 (2, M+29), 352 [21, (M+H)+], 194 (100), 159 (56), 105 (18). Anal. Calcd for 
C22H25NO3: C, 75.19; H, 7.17; N, 3.99. Found (2a/2b): C, 75.46; H, 7.11; N, 4.10.
(1R,2R,3R,5S)-2-Isopinocampheyl N-Benzoyl-(S)-alaninate (1a)/(1R,2R,3R,5S)-2-
Isopinocampheyl N-Benzoyl-(R)-alaninate (1b): From (1R,2R,3R,5S)-isopinocampheol 
(250 mg, 1.62 mmol) and N-benzoylalanyl chloride16 (377 mg, 1.78 mmol), following 
General Procedure A, was obtained 1 (528 mg, 99%) as mixture (1:1) of diastereomers. 
Listed NMR peaks are common to both diastereomers, unless otherwise stated: 1H NMR 
(360 MHz, CDCl3) δ 0.95 (s, 3 H), 1.04 (d, J = 3 Hz, 1 H; from one diast.), 1.07 (d, J = 3 
Hz, 1 H; from other diast.), 1.11 (d, J = 7 Hz, 3 H), 1.22 (s, 3 H), 1.51 (d, J = 7 Hz, 3 H; 
from one diast.), 1.52 (d, J = 7 Hz, 3 H; from other diast.), 1.63–1.69 (ddd, J = 3, 4, 14 Hz, 1 
H; from one diast.), 1.71–1.77 (ddd, J = 3, 4, 14 Hz, 1 H; from other diast.), 1.80–1.85 (m, 1 
H), 1.91–1.96 (m, 1 H), 2.09–2.18 (m, 1 H), 2.33–2.41 (m, 1 H), 2.54–2.63 (m, 1 H), 4.72–
4.79 (dq, J = 5, 7 Hz, 1 H; from one diast.), 4.74–4.81 (dq, J = 5, 7 Hz, 1 H; from other 
diast.), 5.08–5.13 (app quintet, J = 5 Hz, 1 H; from one diast.), 5.09–5.14 (app quintet, J = 5 
Hz, 1 H; from other diast.), 6.81 (broad s, 1 H), 7.40–7.48 (m, 2 H), 7.49–7.52 (m, 1 H), 
7.78–7.81 (m, 1 H). Anal. Calcd for C20H27NO3: C, 72.92; H, 8.26; N, 4.25. Found (1a/1b): 
C, 72.96; H, 8.23; N, 4.36.
General Procedure B
(1R,2S,5R)-8-Phenylmenthyl N-Benzoyl-(S)-α-methylphenylalaninate (9): To a solution 
of diisopropylamine (120 μL, 0.797 mmol) and HMPA (1.6 mL) in THF (8 mL) at −78 °C 
was added n-butyllithium (0.62 mL, 1.28 M in n-hexane), and the resulting solution was 
stirred for 30 min at 0 °C, then cooled to −78 °C. Then, 3a (250 mg, 0.613 mmol) in THF (8 
mL) at −78 °C was added via cannula, followed by n-butyllithium (1.15 mL, 1.3 M in n-
hexane), and the resulting deep red solution stirred for 1 h at −78°C. Benzyl bromide (115 
mg, 0.675 mmol) in THF (1 mL) at −78 °C was then added via cannula. After stirring at 
−78 °C for 45 min, the reaction mixture was poured into ether (30 mL) and NH4Cl (aq, 30 
mL). After further extraction with ether (3 x 20 mL), the combined organics were dried 
(MgSO4), filtered, evaporated, and chromatographed (10% EtOAc/hexane) to give 9 (229 
mg, 75%, 88% de) as a white solid. One recrystallization (50 mg) from ether provided an 
analytical sample of 9 (34 mg, 100% de): mp 149–151°C; 1H NMR (500 MHz, CDCl3) δ 
0.88–2.19 (m, 8 H), 0.95 (d, J = 6 Hz, 3 H), 1.26 (s, 3 H), 1.32 (s, 3 H), 1.60 (s, 3 H), 3.29 
(d, J = 14 Hz, 1 H), 3.35 (d, J = 14 Hz, 1 H), 4.97–5.02 (app dt, J = 4, 11 Hz, 1 H), 6.58 (s, 1 
H), 7.16–7.35 (m, 10 H), 7.44–7.47 (m, 2 H), 7.53–7.56 (m, 1 H), 7.70–7.72 (m, 2 H); 13C 
NMR (125 MHz, CDCl3) δ 21.7, 23.4, 25.8, 27.3, 28.2, 31.4, 34.5, 40.1, 40.3, 41.6, 49.9, 
61.2, 77.8, 125.4, 125.6, 126.7, 126.9, 128.1, 128.2, 128.5, 130.5, 131.4, 135.2, 136.6, 
151.0, 166.9, 173.3. Anal. Calcd for C33H39NO3: C, 79.64; H, 7.90; N, 2.81. Found: C, 
79.61; H, 7.83; N, 2.82.
(1R,2R,3R,5S)-2-Isopinocampheyl N-Benzoyl-(S)-α-methylphenylalaninate (7a)/(1R,2R,
3R,5S)-2-Isopinocampheyl N-Benzoyl-(R)-α-methylphenylalaninate (7b): From 1a/1b 
(30.0 mg, 91 μmol) and benzyl bromide (16.0 mg, 91 μmol), following General Procedure B, 
was obtained 7a/7b (30.3 mg, 79%, 6% de) after flash chromatography (10% EtOAc/
hexane). Major diastereomer: 1H NMR (500 MHz, CDCl3) δ 0.96 (s, 3 H), 1.05–1.09 (m, 1 
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H), 1.17 (d, J = 7 Hz, 3 H), 1.24 (s, 3 H), 1.65–1.67 (app t, J = 3.5 Hz, 1 H), 1.81 (s, 3 H), 
1.83–1.87 (m, 1 H), 1.93–1.98 (m, 1 H), 2.26–2.29 (m, 1 H), 2.37–2.42 (m, 1 H), 2.57–2.63 
(m, 1 H), 3.33 (d, J = 14 Hz, 1 H), 3.76 (d, J = 14 Hz, 1 H), 5.10–5.14 (app quintet, J = 4.5 
Hz, 1 H), 6.89 (s, 1 H), 7.11–7.13 (m, 2 H), 7.18–7.20 (m, 3 H), 7.38–7.41 (m, 2 H), 7.46–
7.49 (m, 1 H), 7.67–7.68 (m, 2 H). Minor diastereomer: 1H NMR (500 MHz, CDCl3) δ 0.97 
(s, 3 H), 1.05–1.09 (m, 1 H), 1.12 (d, J = 7 Hz, 3 H), 1.24 (s, 3 H), 1.68–1.70 (app t, J = 3.5 
Hz, 1 H), 1.79 (s, 3 H), 1.83–1.87 (m, 1 H), 1.93–1.98 (m, 1 H), 2.10–2.13 (m, 1 H), 2.37–
2.42 (m, 1 H), 2.57–2.63 (m, 1 H), 3.30 (d, J = 14 Hz, 1 H), 3.72 (d, J = 14 Hz, 1 H), 5.10–
5.14 (app quintet, J = 4.5 Hz, 1 H), 6.84 (s, 1 H), 7.11–7.13 (m, 2 H), 7.18–7.20 (m, 3 H), 
7.38–7.41 (m, 2 H), 7.46–7.49 (m, 1 H), 7.67–7.68 (m, 1 H). Anal. Calcd for C27H33NO3: 
C, 77.29; H, 7.93; N, 3.34. Found (7a/7b): C, 77.16; H, 8.12; N, 3.36.
(1R,2S)-2-Phenylcyclohexyl N-Benzoyl-(S)-α-methylphenylalaninate (8a)/(1R,2S)-2-
Phenylcyclohexyl N-Benzoyl-(R)-α-methylphenylalaninate (8b): From 2a/2b (30 mg, 85 
μmol) and benzyl bromide (16 mg, 94 μmol), following General Procedure B, was obtained 
8a/8b (22 mg, 57%, 10% de) after SiO2 chromatography (10% EtOAc/hexane): Major 
diastereomer: 1H NMR (500 MHz, CDCl3) δ 0.87–2.25 (m, 8 H), 1.16 (s, 3 H), 2.75–2.80 
(m, 1 H), 3.06 (d, J = 14 Hz, 1 H), 3.62 (d, J = 14 Hz, 1 H), 5.06–5.11 (app dt, J = 4, 11 Hz, 
1 H), 6.40 (d, J = 8 Hz, 1 H), 6.75 (s, 1 H), 6.95–6.99 (m, 1 H), 7.01–7.08 (m, 1 H), 7.14–
7.45 (m, 9 H), 7.47–7.49 (m, 1 H), 7.53–7.59 (m, 2 H). Minor diastereomer: 1H NMR (500 
MHz, CDCl3) δ 0.87–2.25 (m, 8 H), 1.57 (s, 3 H), 2.75–2.80 (m, 1 H), 2.95 (d, J = 14 Hz, 1 
H), 3.45 (d, J = 14 Hz, 1 H), 4.96–5.01 (app dt, J = 4, 11 Hz, 1 H), 6.40 (d, J = 8 Hz, 1 H), 
6.58 (s, 1 H), 6.95–6.99 (m, 1 H), 7.01–7.08 (m, 1 H), 7.14–7.45 (m, 9 H), 7.47–7.49 (m, 1 
H), 7.53–7.59 (m, 2 H). Anal. Calcd for C29H31NO3: C, 78.88; H, 7.07; N, 3.17. Found (8a/
8b): C, 78.84; H, 7.32; N, 3.08.
(1R,2S,5R)-8-Phenylmenthyl N-Benzoyl-(S)-α-methylisovalinate (10)24: From 3a (250 
mg, 0.613 mmol) and iodoethane (105 mg, 0.675 mmol), following General Procedure B, 
was obtained 10 (180 mg, 68%, 86% de), after SiO2 chromatography (10% EtOAc/hexane): 
1H NMR (500 MHz, CDCl3) δ 0.75–1.62 (m, 6 H), 0.81 (t, J = 7 Hz, 3 H), 0.89 (d, J = 6 Hz, 
3 H), 1.27 (s, 3 H), 1.38 (s, 3 H), 1.56 (s, 3 H), 1.75–1.83 (m, 1 H), 2.00–2.09 (m, 2 H), 
2.36–2.43 (m, 1 H), 4.96–5.01 (app dt, J = 4, 10.5 Hz, 1 H), 7.02 (s, 1 H), 7.14–7.17 (m, 1 
H), 7.25–7.31 (m, 4 H), 7.43–7.52 (m, 3 H), 7.74–7.80 (m, 2 H); 13C NMR (125 MHz, 
CDCl3) δ 8.4, 21.7, 22.1, 25.4, 27.2, 28.9, 29.1, 31.4, 34.4, 40.2, 41.6, 49.9, 61.4, 77.3, 
125.4, 125.6, 126.9, 128.1, 128.5, 131.3, 135.2, 150.6, 166.2, 174.3; MS (methane-CI) 436 
[1, (M + H)+], 222 (100), 176 (20), 105 (57). Anal. Calcd for C28H37NO3: C, 77.20; H, 
8.56; N, 3.22. Found: C, 77.10; H, 8.68; N, 3.22.
N-Benzoyl-(S)-α-methylaspartic Acid α-(1R,2S,5R)-8-Phenylmenthyl, β-tert-Butyl 
Ester (11): From 3a (250 mg, 0.613 mmol) and tert-butyl bromoacetate (132 mg, 0.675 
mmol), following General Procedure B, was obtained 11 (276 mg, 86%, 82% de), after flash 
chromatography (10% EtOAc/hexane): 1H NMR (500 MHz, CDCl3) δ 0.78–1.59 (m, 6 H), 
0.85 (d, J = 6 Hz, 3 H), 1.25 (s, 3 H), 1.35 (s, 3 H), 1.37 (s, 9 H), 1.50 (s, 3 H), 2.03–2.13 
(m, 2 H), 2.63 (d, J = 17 Hz, 1 H), 3.33 (d, J = 17 Hz, 1 H), 4.96–5.01 (app dt, J = 4, 10.5 
Hz, 1 H), 7.13–7.16 (m, 1 H), 7.25–7.31 (m, 4 H), 7.39–7.48 (m, 4 H), 7.75–7.77 (m, 2 H); 
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13C NMR (75 MHz, CDCl3) δ 21.7, 22.3, 25.9, 27.2, 28.0, 28.3, 31.3, 34.5, 40.1, 40.9, 41.2, 
49.8, 58.1, 77.6, 81.1, 125.4, 125.6, 126.9, 128.1, 128.5, 131.3, 135.0, 150.9, 166.4, 169.9, 
173.2. Anal. Calcd for C32H43NO5: C, 73.67; H, 8.31; N, 2.69. Found: C, 73.55 H, 8.59; N, 
2.59.
(1R,2S,5R)-8-Phenylmenthyl N-Benzoyl-O-benzyl-(S)-α-methylserinate (12)24: From 3a 
(250 mg, 0.613 mmol) and benzyloxymethyl bromide (136 mg, 0.675 mmol), following 
General Procedure B, was obtained 12 (214 mg, 66%, 78% de), after flash chromatography 
(10% EtOAc/hexane): 1H NMR (500 MHz, CDCl3) δ 0.75–1.54 (m, 6 H), 0.80 (d, J = 6 Hz, 
3 H), 1.21 (s, 3 H), 1.31 (s, 3 H), 1.44 (s, 3 H), 1.97–2.02 (m, 2 H), 3.65 (d, J = 9 Hz, 1 H), 
4.03 (d, J = 9 Hz, 1 H), 4.43 (d, J = 12 Hz, 1 H), 4.49 (d, J = 12 Hz, 1 H), 4.93–4.98 (app dt, 
J = 4, 11 Hz, 1 H), 7.09–7.18 (m, 1 H), 7.21–7.28 (m, 10 H), 7.40–7.43 (m, 2 H), 7.47–7.50 
(m, 1 H), 7.71–7.75 (m, 2 H); 13C NMR (75 MHz, CDCl3) δ 18.9, 21.6, 25.4, 27.1, 28.5, 
31.3, 34.4, 40.1, 41.3, 49.9, 61.3, 72.1, 73.4, 77.6, 125.4, 125.5, 126.9, 127.0, 127.6, 128.1, 
128.3, 128.5, 131.5, 134.9, 137.8, 150.7, 167.1, 172.6. Anal. Calcd for C34H41NO4: C, 
77.39; H, 7.83; N, 2.65. Found: C, 77.12; H, 7.67; N, 2.64.
(1R,2S,5R)-8-Phenylmenthyl N-Benzoyl-(S)-α-methylcinnamylglycinate (13)24: From 3a 
(30 mg, 74 μmol) and trans-cinnamyl bromide (16 mg, 81 μmol), following General 
Procedure B, was obtained 13 (26 mg, 66%, 88% de), after chromatography (10% EtOAc/
hexane): 1H NMR (500 MHz, CDCl3) δ 0.78–1.60 (m, 6 H), 0.79 (d, J = 6 Hz, 3 H), 1.24 (s, 
3 H), 1.35 (s, 3 H), 1.57 (s, 3 H), 1.98–2.01 (m, 1 H), 2.04–2.10 (m, 1 H), 2.64–2.68 (dd, J = 
7, 14 Hz, 1 H), 3.19–3.24 (dd, J = 7, 14 Hz, 1 H), 4.94–5.01 (app dt, J = 4, 10.5 Hz, 1 H), 
5.99–6.04 (app quintet, J = 8 Hz, 1 H), 6.99 (s, 1 H), 7.12–7.21 (m, 2 H), 7.23–7.35 (m, 8 
H), 7.38–7.41 (m, 2 H), 7.45–7.48 (m, 1 H), 7.73–7.75 (m, 2 H); 13C NMR (75 MHz, 
CDCl3) δ 21.7, 22.3, 25.5, 27.2, 28.7, 31.4, 34.4, 39.4, 40.1, 42.0, 49.9, 60.8, 77.6, 123.8, 
125.4, 125.6, 126.2, 126.9, 127.4, 128.1, 128.4, 128.5, 131.4, 134.2, 135.2, 137.0, 150.7, 
166.5, 173.7; MS (EI) 523 (0.14, M+), 402 (8), 188 (78), 105 (100); HRMS (EI) calcd for 
C35H41NO3 523.3086, obsd 523.3069.
(1R,2S,5R)-8-Phenylmenthyl N-Benzoyl-(S)-α-methylpropargylglycinate (14)24: From 
3a (30 mg, 74 μmol) and propargyl bromide (9.6 mg, 81 μmol), following General 
Procedure B, was obtained 14 (22 mg, 67%, 86% de), after SiO2 chromatography (10% 
EtOAc/hexane): 1H NMR (500 MHz, CDCl3) δ 0.81–1.61 (m, 6 H), 0.89 (d, J = 6 Hz, 3 H), 
1.25 (s, 3 H), 1.34 (s, 3 H), 1.51 (s, 3 H), 1.96 (app t, J = 2 Hz, 1 H), 2.05–2.15 (m, 2 H), 
2.73–2.77 (dd, J = 2, 17 Hz, 1 H), 2.99–3.03 (dd, J = 2, 17 Hz, 1 H), 4.95–5.00 (app dt, J = 
4, 10.5 Hz, 1 H), 6.96 (s, 1 H), 7.15–7.18 (m, 1 H), 7.26–7.32 (m, 4 H), 7.42–7.45 (m, 2 H), 
7.49–7.53 (m, 1 H), 7.77–7.79 (m, 2 H); 13C NMR (125 MHz, CDCl3) δ 21.7, 22.0, 26.1, 
26.2, 27.2, 27.9, 31.4, 34.5, 40.0, 41.3, 49.8, 59.3, 71.1, 77.8, 79.6, 125.4, 125.5, 127.0, 
127.1, 128.2, 128.5, 131.5, 150.9, 166.7, 172.6; MS (EI) 445 (2, M+), 406 (2, -C3H3), 232 
(71), 186 (36); HRMS (EI) calcd for C29H35NO3 445.2617, obsd 445.2612.
(1R,2S,5R)-8-Phenylmenthyl N-Benzoyl-(S)-α-methylallylglycinate (15)24: From 3a 
(30.0 mg, 74 μmol) and allyl bromide (9.8 mg, 81 μmol), following General Procedure B, 
was obtained 15 (23 mg, 69%, 88% de), after flash chromatography (10% EtOAc/hexane): 
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1H NMR (500 MHz, CDCl3) δ 0.80–1.60 (m, 6 H), 0.87 (d, J = 6 Hz, 3 H), 1.25 (s, 3 H), 
1.36 (s, 3 H), 1.54 (s, 3 H), 1.99–2.09 (m, 2 H), 2.49–2.53 (dd, J = 7, 14 Hz, 1 H), 2.96–3.00 
(dd, J = 7, 14 Hz, 1 H), 4.93–4.98 (app dt, J = 4, 10.5 Hz, 1 H), 5.08–5.09 (d, J = 8 Hz, 1 H), 
5.09–5.12 (d, J = 15 Hz, 1 H), 5.59–5.66 (m, 1 H), 6.87 (s, 1 H), 7.12–7.15 (m, 1 H), 7.23–
7.31 (m, 4 H), 7.40–7.43 (m, 2 H), 7.47–7.50 (m, 1 H), 7.73–7.75 (m, 2 H); 13C NMR (75 
MHz, CDCl3) δ 21.7, 22.2, 25.6, 27.2, 28.6, 31.4, 34.4, 40.1, 40.3, 41.7, 49.9, 60.1, 77.4, 
119.4, 125.4, 125.6, 126.8, 128.1, 128.5, 131.3, 132.3, 135.2, 150.8, 166.4, 173.7. Anal. 
Calcd for C29H37NO3: C, 77.82; H, 8.33; N, 3.13. Found: C, 77.61; H, 8.46; N, 3.00.
(1R,2S,5R)-8-Phenylmenthyl N-Benzoyl-(S)-α-methylleucinate (16): From 3a (200 mg, 
0.491 mmol) and isobutyl iodide (99.3 mg, 0.540 mmol), following General Procedure B, 
was obtained 16 (196 mg, 86%, 78% de), after SiO2 chromatography (10% EtOAc/hexane): 
1H NMR (300 MHz, CDCl3) δ 0.75–1.71 (m, 8 H), 0.85–0.95 (m, 9 H), 1.25 (s, 3 H), 1.37 
(s, 3 H), 1.55 (s, 3 H), 2.03–2.15 (m, 2 H), 2.28–2.35 (dd, J = 6, 14 Hz, 1 H), 4.93–5.01 (app 
dt, J = 4, 10.5 Hz, 1 H), 7.10–7.20 (m, 2 H), 7.22– 7.33 (m, 4 H), 7.38–7.51 (m, 3 H), 7.73–
7.79 (m, 2 H); 13C NMR (75 MHz, CDCl3) δ 21.7, 23.4, 24.0, 25.1, 25.4, 27.3, 28.8, 31.4, 
34.4, 40.1, 41.5, 43.8, 49.8, 60.8, 77.7, 125.4, 125.5, 126.8, 128.1, 128.5, 131.3, 135.3, 
150.6, 166.2, 175.0. Anal. Calcd for C30H41NO3: C, 77.71; H, 8.91; N, 3.02. Found: C, 
77.86; H, 8.73; N, 2.86.
3,4-Bis(tert-butyldimethylsilyloxy)toluene (17): To a solution of 3-methylcatechol (1.0 g, 
8.1 mmol), 4-(dimethylamino)pyridine (98 mg, 81 μmol), and imidazole (2.2 g, 32 mmol) in 
DMF (50 mL) was added tert-butyldimethylsilyl chloride (3.04 g, 20.1 mmol). The resulting 
reaction mixture was heated at 50 °C for 4 h and then poured into NaHCO3 (aq, 75 mL) and 
Et2O (50 mL). The aqueous layer was further extracted with Et2O (2 x 50 mL) and the 
combined extracts were dried (MgSO4) and evaporated. Chromatrography (20% EtOAc/
hexane) provided 17 (2.82 g, 99%): 1H NMR (360 MHz, CDCl3) δ 0.18 (s, 6 H), 0.19 (s, 6 
H), 0.97 (s, 9 H), 0.98 (s, 9 H), 2.21 (s, 3 H), 6.58–6.71 (m, 3 H); MS (methane-CI) 381 (6, 
M+29), 353 [30, (M+H)+], 337 (47), 295 (100), 115 (40). Anal. Calcd for C19H36O2Si2: C, 
64.71; H, 10.29. Found: C, 64.72; H, 10.08.
3,4-Bis(tert-butyldimethylsilyloxy)benzyl Bromide (18): To a solution of 17 (1.50 g, 4.26 
mmol), N-bromosuccinimide (835 mg, 4.69 mmol), and K2CO3 (60 mg, 43 μmol) in CCl4 (9 
mL) was added benzoyl peroxide (103 mg, 0.426 mmol). The resulting reaction mixture was 
heated to reflux for 12 h and then cooled to 0 °C. Hexane (20 mL) was added, and the 
mixture filtered. The filtrate was washed with NaHCO3 (aq, 5 mL) and H2O (2 x 5 mL). The 
organic layer was dried (MgSO4) and evaporated to afford 18 (1.74 g, 95%) as a pale yellow 
oil: 1H NMR (360 MHz, CDCl3) δ 0.18 (s, 6 H), 0.19 (s, 6 H), 0.97 (s, 9 H), 0.98 (s, 9 H), 
4.42 (s, 2 H), 6.73–6.76 (m, 1 H), 6.81–6.86 (m, 2 H); MS (EI) 432 (1.5, M+ for 81Br), 430 
(1.5, M+ for 79Br), 375 (3.5), 373 (3.3), 351 (13), 73 (100); HRMS (EI) calcd for 
C19H35O2Si2Br (79Br) 430.1343, obsd 430.1343.
(1R,2S,5R)-8-Phenylmenthyl N-Benzoyl-3′,4′-Bis(tert-butyldimethylsilyloxy)-(S)-α-
methylphenylalaninate (19)24: From 3a (300 mg, 0.736 mmol) and 18 (349 mg, 0.810 
mmol), following General Procedure B, was obtained 19 (402 mg, 72%, 88% de), after flash 
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chromatography (10% EtOAc/hexane): 1H NMR (500 MHz, CDCl3) δ 0.07 (s, 3 H), 0.08 (s, 
3 H), 0.15 (s, 3 H), 0.16 (s, 3 H), 0.85–1.62 (m, 6 H), 0.89 (d, J = 6 Hz, 3 H), 0.91 (s, 9 H), 
0.95 (s, 9 H), 1.23 (s, 3 H), 1.32 (s, 3 H), 1.49 (s, 3 H), 1.99–2.14 (m, 2 H), 3.06 (d, J = 14 
Hz, 1 H), 3.10 (d, J = 14 Hz, 1 H), 4.90–4.95 (app dt, J = 4, 11 Hz, 1 H), 6.49 (s, 1 H), 5.64–
6.57 (m, 1 H), 6.59 (s, 1 H), 6.67 (d, J = 8 Hz, 1 H), 7.13–7.16 (m, 1 H), 7.23–7.31 (m, 4 H), 
7.36–7.41 (m, 2 H), 7.45–7.49 (m, 1 H), 7.64–7.66 (m, 2 H); 13C NMR (125 MHz, CDCl3) 
δ −4.24, −4.18, −4.14, −4.03, 18.3, 18.4, 21.3, 23.1, 25.8, 25.9, 27.3, 28.1, 31.3, 31.4, 34.5, 
39.9, 40.0, 41.4, 49.9, 60.7, 77.5, 120.3, 120.4, 123.3, 123.5, 125.2, 125.3, 125.5, 127.0, 
128.1, 128.2, 128.4, 128.7, 129.5, 131.3, 135.0, 145.8, 146.3, 151.1, 166.6, 173.4; HRMS 
(FAB, 3-NOBA, LiI) calcd for C45H67NO5Si2Li [(M+Li)+] 764.4718, obsd 764.4718.
General Procedure C
(S)-α-Methylphenylalanine (20): A suspension of 9 (110 mg, 211 μmol) in 9 N HCl (2.2 
mL) was heated at 120 °C in a sealed vessel for 7 h. The crude reaction mixture was 
extracted with CH2Cl2 (30 mL) and the aqueous layer evaporated in vacuo. The residue was 
applied to a Dowex 50 X 8 ion exchange column. After washing with several column 
volumes of H2O, elution with 10% NH4OH afforded 20 (20.9 mg, 53%) as a white solid: 
[α]D (88% ee) −18.9° (c = 1.0, H2O) [Lit.32 [α]D −21.5° (c 1, H2O)].
(S)-α-Methylaspartate (21): From 11 (150 mg, 287 μmol) in 9 N HCl (2.8 mL), following 
General Procedure C, was obtained 21 (24.2 mg, 58%) as a white solid: [α]D (82% ee) 
+43.1° (c 1.2, H2O) [Lit.6g [α]D +52.8° (c 0.60, H2O)].
(S)-α-Methylleucine (22): From 12 (150 mg, 323 μmol) in 9 N HCl (3.2 mL), following 
General Procedure C, was obtained 22 (20.2 mg, 43%) as a white solid: [α]D (78% ee) 
+26.1° (c 1.0, H2O) [Lit.33 [α]D +34.2° (c 3, H2O)].
General Procedure D
N-Benzoyl-(S)-α-methylphenylalanine (23): To a solution of 9 (30.0 mg, 60.3 μmol) and 
18-crown-6 (16.0 mg, 60.3 μmol) in benzene (2 mL) was added KO2 (26.0 mg, 362 μmol) 
was stirred at 50 °C for 4 d. The resulting mixture was partitioned between K2CO3 (aq, 5 
mL) and Et2O (10 mL). The organic layer was dried (MgSO4), filtered, and evaporated to 
give (−)-8-phenylmenthol25 (14 mg, 76 %). The aqueous layer was acidified to pH 2 with 
10% KHSO4 and then extracted with Et2O. The extract was dried (MgSO4), filtered, 
evaporated, and chromatographed (1:1:0.1 EtOAc/hexane/acetic acid) to give 23 (12.4 mg, 
73%): 1H NMR (300 MHz, DMSO) δ 1.32 (s, 3 H), 3.03 (d, J = 13 Hz, 1 H), 3.48 (d, J = 13 
Hz, 1 H), 7.07–7.09 (m, 2 H), 7.19–7.26 (m, 3 H), 7.42–7.55 (m, 3 H), 7.76–7.79 (m, 2 H), 
8.16 (s, 1 H), 12.44 (s, 1 H); MS (EI) 283 (1.6, M+), 192 (22), 105 (100), 91 (13); HRMS 
(EI) calcd for C17H17NO3 283.1208, obsd 283.1202.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Scheme 1. 
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Scheme 2. 
Acyclic Chiral Alanine Dianions: Diastereofacial Biases
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Scheme 3. 
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Table 1
Enantiomerically Enriched α-Methyl Amino Acidsa
RX Protected Amino Acid Yield Diast. Ratiod
PhCH2Br α-Methylphenylalanine(9) 75% 94:6 (≥99:1)e
CH3CH2I Isovalinec (10) (α-Methylbutyrine) 68% 93:7
t-BuO2CCH2Br α-Methylaspartate(11) 86% 91:9
PhCH2OCH2Br α-Methylserinec (12) 77% 89:11
PhCH=CHCH2Br α-Methyl-cinnamylglycinec(13) 66% 94:6
HCCCH2Br α-Methylpropargylglycinec(14) 67% 93:7
H2C=CHCH2Br α-Methylallylglycine(c15) 69% 94:6
(CH3)2CHCH2I α-Methylleucine (16) 86% 89:11
ArCH2Brb α-Methyl-DOPAc(19) 72% 94:6
a
R*OH = (−)-8-phenylmenthol.
bAr = 3,4-bis(t-butyldimethylsilyloxy)phenyl.
c
Footnote 24.
d
Footnote 22.
eAfter a single recrystallization (68% recryst. yield).
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